{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:04Z","timestamp":1789625104659,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>\n                      Triple-negative breast cancer (TNBC) with germline\n                      <jats:italic toggle=\"yes\">PALB2 (gPALB2<\/jats:italic>\n                      ) mutations represents a rare but actionable subset sensitive to poly(ADP-ribose) polymerase (PARP) inhibition. However, clinical evidence supporting PARP inhibition combined with programmed cell death protein 1 (PD-1) blockade after progression on prior immunotherapy remains limited, particularly in central nervous system-involved disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 61-year-old woman initially diagnosed with stage I TNBC developed chest wall recurrence and occipital bone metastasis after a 2-year disease-free interval. The disease subsequently progressed to spinal leptomeningeal metastasis, causing complete bilateral lower-limb paralysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>\n                      Recurrent metastatic TNBC with programmed death-ligand 1 expression and leptomeningeal and multiple osseous metastases was diagnosed. Pharmacogenomic profiling identified a pathogenic\n                      <jats:italic toggle=\"yes\">gPALB2<\/jats:italic>\n                      p.L484* mutation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>First-line liposomal doxorubicin achieved 9 months of disease control. Second-line nab-paclitaxel plus tislelizumab, a PD-1 inhibitor, provided a progression-free survival of only 2 months. Third-line carboplatin plus tislelizumab induced rapid neurological improvement, but carboplatin was discontinued after 2 months due to hematologic toxicity. Maintenance tislelizumab monotherapy was continued for an additional 5 months until neurological deterioration and a new femoral metastasis indicated disease progression. Olaparib was subsequently added to continued tislelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Following olaparib initiation, bilateral lower-limb muscle strength improved from Medical Research Council grade 0 to grade 2. Follow-up imaging demonstrated marked regression of the leptomeningeal and osseous lesions. The patient achieved a durable progression-free survival of approximately 40 months with acceptable tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>\n                      Identification of a\n                      <jats:italic toggle=\"yes\">gPALB2<\/jats:italic>\n                      mutation informed the addition of olaparib to continued tislelizumab, leading to sustained disease control in this patient. Although the relative contributions of each component cannot be determined from a single case, this hypothesis-generating observation suggests that PARP inhibitor\u2013based strategies and continuation of PD-1 blockade beyond progression warrant further investigation in carefully selected patients with\n                      <jats:italic toggle=\"yes\">gPALB2<\/jats:italic>\n                      -mutated TNBC with central nervous system involvement.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050334","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:06:30Z","timestamp":1787331990000},"page":"e50334","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6495-3391","authenticated-orcid":false,"given":"Yulei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"},{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"},{"name":"Department of Breast Surgery, Maoming People\u2019s Hospital, Maoming, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Maoming People\u2019s Hospital, Maoming, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Maoming People\u2019s Hospital, Maoming, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-2930","authenticated-orcid":false,"given":"Guochun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China"},{"name":"Department of Breast Cancer, Guangdong Provincial People\u2019s Hospital\u2019s Nanhai Hospital, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1097\/JS9.0000000000001799","article-title":"Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis.","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"e70803","DOI":"10.1002\/cam4.70803","article-title":"Targeting triple-negative breast cancer: resistance mechanisms and therapeutic advancements.","volume":"14","author":"Raman","year":"2025","journal-title":"Cancer Med"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer.","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer.","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat Genet"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/0008-5472.CAN-22-1535","article-title":"BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer.","volume":"82","author":"Foo","year":"2022","journal-title":"Cancer Res"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","article-title":"Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.","volume":"16","author":"Cybulski","year":"2015","journal-title":"Lancet Oncol"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/cncr.31307","article-title":"PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside.","volume":"124","author":"Turk","year":"2018","journal-title":"Cancer"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes.","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41523-020-00174-9","article-title":"Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.","volume":"6","author":"Kuemmel","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status.","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.18632\/aging.102783","article-title":"Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.","volume":"12","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/tbcr-23-39","article-title":"Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer.","volume":"5","author":"Yu","year":"2024","journal-title":"Transl Breast Cancer Res"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study.","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.3390\/cells11233877","article-title":"The BRCAness landscape of cancer.","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2025-CT004","article-title":"Abstract CT004: KEYLYNK-007: tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency-positive advanced cancers.","volume":"85","author":"Yap","year":"2025","journal-title":"Cancer Res"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/1078-0432.CCR-25-1818","article-title":"KEYLYNK-009: pembrolizumab plus olaparib in locally recurrent inoperable or metastatic triple-negative breast cancer after clinical benefit from first-line pembrolizumab plus chemotherapy.","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin Cancer Res"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"102410","DOI":"10.1016\/j.tranon.2025.102410","article-title":"Therapeutic advances and application of PARP inhibitors in breast cancer.","volume":"57","author":"Zhou","year":"2025","journal-title":"Transl Oncol"},{"key":"R25-20260917","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria.","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:01:18Z","timestamp":1789624878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050334"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":25,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050334","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2025-10-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}